HER-Directed Therapies in Metastatic Breast Cancer: Safety and Efficacy Considerations

Oncology
Curriculum:
HER-Directed Therapies in Metastatic Breast Cancer: Safety and Efficacy Considerations
Credits:
0.50 AMA PRA Category 1 Credit(s)
Launch Date:
February 22, 2021
Expiration Date:
February 22, 2022

Primary Audience:

Oncologists

Relevant Terms:

Breast Cancer, HER, Metastatic, HER2, HER2-positive

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara A. Hurvitz, MD, FACP, is Professor of Medicine at the University of California, Los Angeles (UCLA); Co-director of the Santa Monica-UCLA Outpatient Oncology Practice; Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center at UCLA; and Director of the Breast Oncology Program. Dr Hurvitz earned her MD from the University of Southern California in Los Angeles. She served her internship/residency at UCLA, was Chief Resident of internal medicine, and completed a hematology-oncology fellowship at UCLA in 2006. Dr Hurvitz is board certified in internal medicine, hematology, and medical oncology. She is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and is a Fellow of the American College of Physicians. 

Dr Hurvitz has won numerous awards, among them the Marni Levine Memorial Breast Cancer Research Award in 2008 through 2015. She has an active clinical practice specializing in the treatment of women with breast cancer. Dr Hurvitz is involved in designing, implementing, and leading multiple national and international clinical trials testing new targeted therapies. She leads the preclinical evaluation of novel breast cancer targets in the Translation Oncology Research Laboratory at UCLA.

Sara M. Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women’s Cancers
Director, Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara M. Tolaney, MD, MPH, is an Assistant Professor of Medicine at Harvard Medical School and Associate Director for the Susan F. Smith Center for Women’s Cancers at Dana-Farber/Brigham and Women’s Cancer Center in Boston, Massachusetts. She received her medical degree from the University of California, San Francisco, and completed her residency in Internal Medicine at Johns Hopkins University in Baltimore, Maryland, and fellowships in Hematology and Medical Oncology at Dana-Farber Cancer Institute. She also earned her master’s degree in public health from Harvard School of Public Health. Her research focuses on the development of novel therapies in the treatment of breast cancer. Dr Tolaney is Principal Investigator of many therapeutic clinical trials and translational studies for breast cancer. She serves as Breast Cancer Leader for the Early Drug Development Center and Center for Immuno-Oncology at Dana-Farber Cancer Institute. Dr Tolaney has developed many novel immunotherapy combination trials, many of which are currently ongoing. She serves on the Scientific Review Committee at Dana-Farber Cancer Institute and Leader of the American Society of Clinical Oncology Metastatic Breast Track Scientific Review Committee. She is the recipient of the Lee M. Nadler “Extra Mile” Award, and the Innovation Award for Clinical Faculty.
1. Describe the latest clinical advances in HER-directed therapies for advanced or metastatic breast cancer
2. Select therapy for advanced or metastatic HER2-positive breast cancer according to the latest evidence and efficacy and safety data
3. Discuss available resources for caring for breast cancer patients during a global pandemic  

This educational activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical Center and Spire Learning.

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

 
PROGRAM OVERVIEW
Dr Hurvitz and Dr Tolaney share key data and expert perspectives on approved and emerging HER-targeted therapies for metastatic breast cancer.
 
TARGET AUDIENCE
Oncologists, oncology nurse practitioners, and oncology physician assistants
 
LEARNING OBJECTIVES
Upon completion of this educational activity, learners should be better able to:
  • DESCRIBE the latest clinical advances in HER-directed therapies for advanced or metastatic breast cancer
  • SELECT therapy for advanced or metastatic HER2-positive breast cancer according to the latest evidence and efficacy and safety data
  • DISCUSS available resources for caring for breast cancer patients during a global pandemic  
 
ACCREDITATION AND CREDIT DESIGNATION 
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and Spire Learning. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
 
 
CREDIT DESIGNATION STATEMENT
Albert Einstein College of Medicine-Montefiore Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
HOW TO RECEIVE CREDIT
To receive credit for your participation in this educational activity:
  • Read the learning objectives, disclosure statements and other introductory CME information
  • Complete the preassessment prior to the start of the activity
  • Participate in the online enduring activity
  • Complete the postassessment with a passing grade of 70% or higher and evaluation at the conclusion of the activity
If you are seeking credit, you must complete the postassessment and evaluation at the conclusion of the activity.
 
For information about the accreditation of this activity, please contact Einstein-Montefiore Center for Continuing Professional Development at cme@montefiore.org or 718-920-6674.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 
DISCLOSURE OF UNLABELED USE
This educational activity does not contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
The planners of this activity do not recommend the use of any agent outside of the labeled indications.
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
CONFLICT OF INTEREST STATEMENT
The “Policy on Collection of Relevant Financial Relationships and Resolution of COI” of Albert Einstein College of Medicine-Montefiore Medical Center requires that faculty participating in any CME activity disclose to the audience any relevant relationship(s) with a commercial interest.* Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine-Montefiore Medical Center also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

*The ACCME defines a Commercial Interest as an entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of the clinical service is owned, or controlled by, an ACCME-defined commercial interest.
 
FACULTY CO-CHAIRS
Sara A. Hurvitz, MD, FACP 
Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
 
Disclosure Statement:
Contracted Research: Ambrx Inc; Amgen Inc; Arvinas; Bayer; Daiichi Sankyo, Inc; Genentech, Inc; GlaxoSmithKline; Lilly; MacroGenics, Inc; Novartis; OBI Pharma; Pfizer Inc; Pieris Pharmaceuticals; Puma Biotechnology Inc; Radius Health, Inc; Roche; Seattle Genetics 
Travel Funds: Lilly
 
Dr Hurvitz has indicated that her disclosures will not impact her ability to provide an unbiased presentation.
 
Sara M. Tolaney, MD, MPH 
Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women’s Cancers
Director, Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Dana-Farber Cancer Institute
Boston, Massachusetts
 
Disclosure Statement:
Research Support (paid to her institution): AstraZeneca; Bristol-Myers Squibb; Cyclacel Pharmaceuticals, Inc; Eisai Inc; Exelixis Inc; Genentech, Inc; Immunomedics; Lilly; Merck & Co; NanoString Technologies, Inc; Nektar Therapeutics; Novartis; Odonate Therapeutics, Inc; Pfizer Inc; Sanofi
Consulting Fees: AbbVie Inc; AstraZeneca; Athenex, Inc; Bristol-Myers Squibb; Celldex Therapeutics; Daiichi Sankyo, Inc; Eisai Inc; G1 Therapeutics, Inc; Genentech, Inc; Immunomedics; Lilly; NanoString Technologies, Inc; Nektar Therapeutics; Novartis; Odonate Therapeutics, Inc; Paxman; Pfizer Inc; Puma Biotechnology Inc; Sanofi; Seattle Genetics; Silverback Therapeutics
 
Dr Tolaney has indicated that her disclosures will not impact her ability to provide an unbiased presentation.
 
Jesus D. Anampa Mesias, MD, MS (Peer Reviewer)
Assistant Professor, Department of Medicine (Oncology)
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York
 

Dr Anampa Mesias has no relevant conflicts of interest with any ACCME-defined commercial interest.

Victor B. Hatcher, PhD (CME Reviewer)
Associate Dean, Continuing Professional Development
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York

Dr Hatcher has no relevant conflicts of interest with any ACCME-defined commercial interest.

Spire Learning:
Mairead Early and Allison Goldberg: No relevant conflicts of interest with any ACCME-defined commercial interest.
Chris Washburn, PhD: Spouse is employed by Janssen Pharmaceuticals, Inc
 
PRIVACY POLICY:
Einstein Policy:
Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting to the ACCME.
 

Einstein maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.

Additional information regarding Albert Einstein College of Medicine-Montefiore Medical Center’s Privacy Policy can be viewed at https://www.mecme.org/PrivacyStatement.aspx.

Spire Learning Privacy Policy:
Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
 
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.
 
Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws. 
 

Copyright Information
Copyright © 2021 by Spire Learning, LLC and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC and Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein) will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above